A new federal law proposed by CMS took effect on Jan. 1, requiring hospitals to publish online price lists for medical imaging and all other services they provide, according to a recent report by Newsweek.

The Sapien 3 Ultra heart valve has received FDA approval for transcatheter aortic valve replacement (TAVR) in patients with severe, symptomatic aortic stenosis who are considered to be at intermediate or high risk of open-heart surgery, device manufacturer Edwards Lifesciences announced on Dec. 28.

When researchers compared brain MRI scans of patients who had previously received gadobutrol, a common gadolinium-based contrast agent (GBCA), with patients not exposed to gadobutrol, they did not observe any visual signal intensity changes. The team noted, however, that patients who received gadobutrol had shorter T1 relaxation times of the globus pallidus.

More than 200 people braved the waters of the chilly Boulder County Reservoir in an effort to raise money for the American Cancer Society for the 37th annual Polar Plunge. Participants raised a total of $30,000 during the event.

Joseph Lamelas, M.D., an internationally recognized expert cardiac surgeon who helped pioneer minimally invasive approaches to cardiac surgery, has joined the University of Miami Health System as chief of cardiothoracic surgery and professor of surgery within the Miller School of Medicine.

Here are AI in Healthcare’s top 10 AI and clinical innovation stories from 2018.

Healthcare stakeholders dealt with a slurry of new regulations, policy shifts and mega deals across the industry in 2018. After a whirlwind of a year, we’ve rounded up our most popular stories from 2018.

John Giannandrea has been named Apple’s senior vice president of machine learning and AI strategy, the company announced Thursday.

Walgreens Boots Alliance has teamed up with Verily, the life sciences unit of Google parent company Alphabet. The two companies will focus on improving outcomes for patients with chronic conditions, CNBC reported.

Patients with diabetes and peripheral artery disease (PAD) are significantly more likely than nondiabetics with PAD to die from cardiovascular causes or have a heart attack or stroke, according to a subanalysis of the EUCLID trial.